[go: up one dir, main page]

ES2191702T3 - Fv monocatenarios anti-egfr y anticuerpos anti-egfr. - Google Patents

Fv monocatenarios anti-egfr y anticuerpos anti-egfr.

Info

Publication number
ES2191702T3
ES2191702T3 ES95913134T ES95913134T ES2191702T3 ES 2191702 T3 ES2191702 T3 ES 2191702T3 ES 95913134 T ES95913134 T ES 95913134T ES 95913134 T ES95913134 T ES 95913134T ES 2191702 T3 ES2191702 T3 ES 2191702T3
Authority
ES
Spain
Prior art keywords
egfr
antibodies
antibody
books
fvs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95913134T
Other languages
English (en)
Inventor
A Cathrine Kettleborough
Mary M Bendig
Keith H Ansell
Detlef Gussow
Jaime Adan
Francesc Mitjans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2191702T3 publication Critical patent/ES2191702T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS ANTICUERPOS ANTI-EGFR Y A CADENAS SIMPLES FVS (SCFVS) DE LOS MISMOS QUE PUEDEN OBTENERSE A PARTIR DE LIBRERIAS DE ANTICUERPOS CONSTRUIDAS A PARTIR DE CELULAS DE UN MAMIFERO INMUNIZADO, PREFERIBLEMENTE UN RATON. DOS DE LOS FVS DE CADENA SIMPLE AISLADOS A PARTIR DE LAS LIBRERIAS DE ANTICUERPOS FUERON MODIFICADOS GENETICAMENTE PARA CREAR MOLECULAS COMPLETAS DE ANTICUERPOS PARCIALMENTE HUMANIZADOS. ESTOS ANTICUERPOS QUIMERICOS ANTI-EGFR CONTIENE REGIONES CONSTANTES DE INMUNOGLOBULINAS HUMANAS Y PUEDEN UTILIZARSE ASI COMO LOS FVS DE CADENA SIMPLE COMO AGENTES PARA LA DIAGNOSIS Y LA TERAPIA DE TUMORES HUMANOS.
ES95913134T 1994-03-17 1995-03-16 Fv monocatenarios anti-egfr y anticuerpos anti-egfr. Expired - Lifetime ES2191702T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94104160 1994-03-17
EP94118970 1994-12-02

Publications (1)

Publication Number Publication Date
ES2191702T3 true ES2191702T3 (es) 2003-09-16

Family

ID=26135522

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95913134T Expired - Lifetime ES2191702T3 (es) 1994-03-17 1995-03-16 Fv monocatenarios anti-egfr y anticuerpos anti-egfr.

Country Status (20)

Country Link
US (1) US5844093A (es)
EP (1) EP0699237B1 (es)
JP (2) JPH08510922A (es)
KR (1) KR100376038B1 (es)
AT (1) ATE232902T1 (es)
AU (1) AU2071695A (es)
CA (1) CA2163012C (es)
CZ (1) CZ292061B6 (es)
DE (1) DE69529649T2 (es)
DK (1) DK0699237T3 (es)
ES (1) ES2191702T3 (es)
HU (1) HU221001B1 (es)
MX (1) MX9504802A (es)
NO (1) NO322252B1 (es)
PL (1) PL181342B1 (es)
PT (1) PT699237E (es)
RU (1) RU2170257C2 (es)
SK (1) SK283889B6 (es)
UA (1) UA41929C2 (es)
WO (1) WO1995025167A1 (es)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT659439E (pt) 1993-12-24 2002-04-29 Merck Patent Gmbh Imunoconjugados
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
AU4373197A (en) * 1996-09-19 1998-04-14 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
JP4215172B2 (ja) * 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
CN1276830A (zh) 1997-09-02 2000-12-13 住友制药株式会社 抗乙型肝炎病毒核心蛋白的单链抗体及其基因和含有它们的乙型肝炎治疗药物
DE19744531A1 (de) * 1997-10-09 1999-05-27 Klaus Dr Rer Nat Bosslet Bindemoleküle gegen Rezeptor-Ligand-Komplexe
CA2309679C (en) 1997-11-17 2010-07-20 Peter Kufer Method of identifying binding site domains that retain the capacity of binding to an epitope
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
DE69901569T2 (de) 1998-08-28 2002-12-19 Genentech, Inc. Humane antikörper gegen faktor ix/ixa
IL146480A0 (en) * 1999-05-14 2002-07-25 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US7361338B2 (en) * 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6790631B1 (en) * 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
CN1239701C (zh) * 2000-05-19 2006-02-01 梨树化学株式会社 抗表皮生长因子受体的人源化抗体
WO2001096401A1 (fr) * 2000-06-14 2001-12-20 Medical & Biological Laboratories Co., Ltd. Procede de construction d'un anticorps scfv fusionne a une proteine fluorescente
US8697394B2 (en) 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7449308B2 (en) * 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
EP2119793A1 (en) * 2000-06-28 2009-11-18 Glycofi, Inc. Methods for producing modified glycoproteins
WO2002011677A2 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20030211106A1 (en) * 2000-08-21 2003-11-13 Tornetta Mark A Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP2316951A1 (en) * 2001-01-17 2011-05-04 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds
DE60232785D1 (de) 2001-03-14 2009-08-13 Myriad Genetics Inc Tsg101-gag-wechselwirkung und ihre verwendung
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CZ200438A3 (cs) * 2001-06-13 2004-06-16 Genmab A/S Název neuveden
EP2399586A1 (en) 2002-01-11 2011-12-28 Jefferies, Dr., Wilfred Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
ES2376165T3 (es) 2002-07-15 2012-03-09 F. Hoffmann-La Roche Ag Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
JP5814494B2 (ja) 2002-11-12 2015-11-17 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
EP1687338B1 (en) 2003-11-07 2010-10-20 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses thereof
PT1735348E (pt) * 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
JP5080243B2 (ja) * 2004-04-21 2012-11-21 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ポリ−Ｎ−アセチルグルコサミン（ＰＮＡＧ／ｄＰＮＡＧ）結合ペプチドおよびその使用方法
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
EP2286844A3 (en) 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
CA2616395C (en) 2005-07-25 2016-10-04 Trubion Pharmaceuticals B-cell reduction using cd37-specific and cd20-specific binding molecules
EA013878B1 (ru) * 2005-12-06 2010-08-30 Домантис Лимитед Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
US7503217B2 (en) * 2006-01-27 2009-03-17 Weatherford/Lamb, Inc. Sonar sand detection
AU2007222165A1 (en) * 2006-03-06 2007-09-13 Agency For Science, Technology And Research Human embryonic stem cell methods and PODXL expression
EP3805269A1 (en) 2006-06-12 2021-04-14 Aptevo Research and Development LLC Single-chain multivalent binding proteins with effector function
EP2975057A1 (en) 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
BRPI0720437A2 (pt) 2006-12-07 2014-01-07 Novartis Ag Anticorpos antafonísticos contra ephb3
US20100034816A1 (en) * 2006-12-22 2010-02-11 Novelix Therapeutics Gmbh Treatment of Diabetes by at Least One Epidermal Growth Factor Receptor Specific Antibody or a Derivative Thereof
EP2126127B1 (en) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
AU2008227123B2 (en) 2007-03-15 2014-03-27 Ludwig Institute For Cancer Research Ltd. Treatment method using EGFR antibodies and src inhibitors and related formulations
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
US9283276B2 (en) 2007-08-14 2016-03-15 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
AU2008302111B2 (en) 2007-09-21 2014-04-24 The Regents Of The University Of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
KR20110013391A (ko) * 2008-04-11 2011-02-09 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Ｃｄ37 면역치료제 및 이작용성 화학치료제와 이의 병용물
MX2010011955A (es) 2008-04-29 2011-01-21 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
RU2010153578A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US8492364B2 (en) 2008-07-21 2013-07-23 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic β-1,6 glucosamine oligosaccharides
KR101108642B1 (ko) * 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011063346A1 (en) * 2009-11-20 2011-05-26 Northshore University Health System Research Institute Targeting of the c-terminal segment of c. difficile toxin b for improved clinical diagnosis, prevention, and treatment
WO2011069104A2 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
CN102167743B (zh) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗egfr单克隆抗体、其制备方法及用途
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
WO2011152525A1 (ja) * 2010-06-04 2011-12-08 東亞合成株式会社 抗体およびその利用
BR112013002578A2 (pt) 2010-08-03 2019-05-14 Abbvie Inc. imunoglobinas de domínio variável duplo e usos das mesmas
KR20130139884A (ko) 2010-08-26 2013-12-23 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
KR101273918B1 (ko) * 2010-09-17 2013-06-13 강원대학교산학협력단 인간 항-상피세포성 성장인자수용체 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물
CN103298489A (zh) 2010-10-29 2013-09-11 伊缪诺金公司 新型egfr结合分子及其免疫偶联物
JP5828902B2 (ja) 2010-10-29 2015-12-09 イミュノジェン， インコーポレイテッド 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
MX355255B (es) 2011-02-04 2018-04-11 Genentech Inc Variantes de fc y métodos para su producción.
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
US9150846B2 (en) 2011-07-05 2015-10-06 Bioasis Technologies, Inc. P97-antibody conjugates and methods of use
EP3321281B1 (en) 2011-08-05 2019-11-27 biOasis Technologies Inc P97 fragments with transfer activity
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
US8791244B2 (en) 2011-09-30 2014-07-29 Regeneron Pharmaceuticals, Inc. Anti-ErbB3 antibodies and uses thereof
EP3559049A4 (en) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF
SG11201402343SA (en) 2011-11-21 2014-06-27 Immunogen Inc Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
US9872904B2 (en) 2012-03-21 2018-01-23 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Photoimmunoconjugates for use in photodynamic therapy
JP6441792B2 (ja) * 2012-05-17 2018-12-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｇｆｒに結合する抗原結合蛋白質
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
ES2647082T3 (es) 2012-07-31 2017-12-19 Bioasis Technologies Inc Proteínas desfosforiladas de la enfermedad de depósito lisosómico y métodos de uso de las mismas
CA2890263C (en) 2012-11-01 2020-03-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
WO2014160438A1 (en) 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
PT3677591T (pt) 2013-04-29 2023-02-17 Teva Pharmaceuticals Australia Pty Ltd Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2015117121A1 (en) 2014-02-03 2015-08-06 Bioasis Technologies, Inc. P97 fusion proteins
US10392605B2 (en) 2014-02-19 2019-08-27 Bioasis Technologies Inc. P97-IDS fusion proteins
WO2015168521A2 (en) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. P97-polynucleotide conjugates
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
CA2943707A1 (en) 2014-05-06 2015-11-12 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells
AU2015273353B2 (en) 2014-06-13 2020-09-10 Tenboron Oy Conjugates comprising an anti-EGFR1 antibody
SG11201703251TA (en) 2014-10-29 2017-05-30 Teva Pharmaceuticals Australia Pty Ltd INTERFERON α2B VARIANTS
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
JP6688551B2 (ja) 2015-05-21 2020-04-28 ハープーン セラピューティクス，インク． 三重特異性結合タンパク質と使用方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP7002446B2 (ja) 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
CN119060177A (zh) 2016-05-20 2024-12-03 哈普恩治疗公司 单结构域血清白蛋白结合蛋白质
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
WO2018152033A1 (en) * 2017-02-14 2018-08-23 Promab Biotechnologies, Inc. Cd47-car-t cells
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018209298A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CN109879964B (zh) * 2017-12-06 2022-08-05 北京科立思维生物科技有限公司 抗egfr单链抗体、抗pd1单链抗体及融合蛋白
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
MX2021001749A (es) 2018-08-13 2021-05-27 Beijing Percans Oncology Co Ltd Biomarcadores para terapia contra el cancer.
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
CA3181566A1 (en) * 2020-04-30 2021-11-04 Board Of Regents, The University Of Texas System Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
CA3187272A1 (en) 2020-10-08 2022-04-14 Thorsten Ross Trispecific binders
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
AU2022382368A1 (en) 2021-11-03 2024-05-02 Affimed Gmbh Bispecific cd16a binders
CN119101160B (zh) * 2024-10-25 2025-02-11 江苏百英生物科技有限公司 一种抗cd28纳米抗体、基于天然库筛选cd28纳米抗体的方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016842A1 (en) * 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US5395750A (en) * 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
GB9401182D0 (en) * 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect

Also Published As

Publication number Publication date
PL181342B1 (pl) 2001-07-31
KR100376038B1 (ko) 2003-06-09
CA2163012A1 (en) 1995-09-21
CA2163012C (en) 2009-12-08
AU2071695A (en) 1995-10-03
ATE232902T1 (de) 2003-03-15
CZ292061B6 (cs) 2003-07-16
WO1995025167A1 (en) 1995-09-21
PL311661A1 (en) 1996-03-04
US5844093A (en) 1998-12-01
SK283889B6 (sk) 2004-04-06
EP0699237B1 (en) 2003-02-19
HU9503285D0 (en) 1996-02-28
EP0699237A1 (en) 1996-03-06
DE69529649T2 (de) 2003-12-18
UA41929C2 (uk) 2001-10-15
DE69529649D1 (de) 2003-03-27
NO954626D0 (no) 1995-11-16
HU221001B1 (hu) 2002-07-29
CZ301495A3 (en) 1996-02-14
SK143095A3 (en) 1996-11-06
PT699237E (pt) 2003-07-31
JPH08510922A (ja) 1996-11-19
JP2006025794A (ja) 2006-02-02
HUT73461A (en) 1996-08-28
NO322252B1 (no) 2006-09-04
NO954626L (no) 1995-11-16
MX9504802A (es) 1997-05-31
DK0699237T3 (da) 2003-05-26
RU2170257C2 (ru) 2001-07-10

Similar Documents

Publication Publication Date Title
ES2191702T3 (es) Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
HUP0100794A1 (hu) Új eljárás humán antigén elleni receptorok előállítására, és azok alkalmazása
PE20050376A1 (es) Anticuerpos dirigidos a m-csf
ATE171472T1 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
DE3751908D1 (de) Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
ATE405679T1 (de) Synthetische humane neutralisierende monoklonale antikörper gegen hiv
FI941572L (fi) Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
DE69233191D1 (de) Cyclin d1 und seine cdna
FI924819A0 (fi) Chimaera anti-icam-i-antikroppar foer maenniskobruk, foerfaranden foer deras framstaellning samt deras anvaendning
BR9607171A (pt) Anticorpos monoclonais anti-cd6 e usos dos mesmos
NO20045645L (no) Noytraliserende humant anti-IGFR-antistoff
ES2191016T3 (es) Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial.
NO20076673L (no) Antistoffer rettet mot CD20 og anvendelser derav
DE3784720D1 (de) Produkt, praeparat und methode zum bekaempfen der allergien.
EP0675904A4 (en) HUMANE NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE VIRUS FROM HUMAN THAT MAKES THE IMMUNE.
DE68924773D1 (de) Monoklonale antikörper gegen den bereich der leichten kette von menschlichem faktor xii sowie methoden zu deren herstellung und verwendung.
ES2173910T3 (es) Anticuerpos humanizados dirigidos contra el antigeno a33.
ATE11547T1 (de) Neue d-homosteroide, ihre verwendung und herstellung, sowie pharmazeutische praeparate damit.
NO965395L (no) Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen
ES2121358T3 (es) Anticuerpos monoclonales humanizados contra interleuquina-4 humana.
ATE414142T1 (de) Anti-ccr5 antikörper
ATE128986T1 (de) Antigen sf-25 des darm-adenokarzinoms sowie antikörper, die dieses antigen erkennen.
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.